Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Maintenance Dose

<< Previous

Bullboard Posts

Next >>

Post by RoseHeavenon Jun 30, 2022 12:40am

368 Views

Post# 34792762

Maintenance Dose

They are giving maintenance dose only to 26 (15 done+11 pending) out of 38 patients treated in Phase II. Does it mean that all 12 underdosed patients were excluded from the maintenance dosage? If underdosed patients were excluded, why they count them as EVALUABLE patients in determining response rate?

I don't get it, will appreciate if anybody could help me to understand.

Thanks

<< Previous

Bullboard Posts

Next >>

98% energy efficiency: How Acceleware's EM Technology is transforming heat solutions